Ten-year outcome of patients with acute myeloid leukemia not treated with allogeneic transplantation in first complete remission

Autor:	Deedra Nicolet, John C. Byrd, Sumithira Vasu, Klaus H. Metzeler, Joseph O. Moore, Krzysztof Mrózek, Heiko Becker, Jessica Kohlschmidt, Dimitrios Papaioannou, Andrew J. Carroll, Clara D. Bloomfield, Gail J. Roboz, Lisa J. Sterling, Maria R. Baer, Bayard L. Powell, Ann-Kathrin Eisfeld, Jonathan E. Kolitz, Richard Stone
Rok vydání:	2018
Předmět:	Adult Male 0301 basic medicine medicine.medical_specialty Myeloid Allogeneic transplantation Adolescent medicine.medical_treatment Abnormal Karyotype Hematopoietic stem cell transplantation Disease-Free Survival 03 medical and health sciences 0302 clinical medicine hemic and lymphatic diseases Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Survival rate Retrospective Studies Myeloid Neoplasia business.industry Age Factors Hematopoietic Stem Cell Transplantation Myeloid leukemia Cancer Retrospective cohort study Hematology Middle Aged Allografts medicine.disease Survival Rate Leukemia Myeloid Acute Leukemia 030104 developmental biology medicine.anatomical_structure 030220 oncology & carcinogenesis Female business Follow-Up Studies
Zdroj:	Blood Advances. 2:1645-1650
ISSN:	2473-9537 2473-9529
Popis:	The probability that adult patients with de novo acute myeloid leukemia (AML) receiving intensive chemotherapy in the absence of allogeneic hematopoietic stem cell transplantation (Allo-HCT) in first complete remission (CR1) will be disease-free at 10 years after diagnosis, a long-term surrogate of cure, is unknown. To address this question, we examined 2551 AML patients (1607 aged
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::da69bcc4921d00c1faa20f95266e296e https://doi.org/10.1182/bloodadvances.2017015222 Zobrazit plný text záznamu